Operational-Risk Appetite Translation Board Adviser

The mandate

The committee repeatedly asks whether its low appetite for missed clinical delivery is meaningful when flights fail, a batch releases late or hospital demand exceeds usable isotope. Enterprise statements describe tolerance, but dispatch teams face decaying product, substitution limits, radiation-security requirements and incomplete patient consequence. Choices escalate until remaining half-life removes the option. Directors want challenge on whether appetite is translated into usable thresholds and delegated decisions before the clock starts.

Three days each month cover evidence preparation, one operational-case challenge, chair consultation and follow-up. Five risk-and-clinical-supply committee sessions and four radiopharmacy or airport-interface reviews are included. A material proposed change to a dispatch, allocation or substitution threshold receives a written challenge within one Czech business day; live cases remain with the accountable executives and clinicians, not the adviser.

The term lasts ten months through a peak treatment season and two continuity simulations. A further appointment requires a fresh resolution identifying a new standing question, evidence that management can apply the translation unaided and renewed conflict disclosure. There is no automatic extension after an incident, and unused time cannot be carried into later product launches or distribution expansions.

The adviser has no line authority and no executive responsibility for quality release, radiation safety, dispatch, clinical substitution, patient priority, aviation contracting, security, incident command or risk acceptance. Management and authorised clinicians own live choices; the board sets appetite. The adviser may test thresholds and delegated pathways but cannot release a batch, allocate supply, direct a courier or determine treatment equivalence.

Relationships with isotope producers, radiopharmacies, airlines, specialist couriers, hospitals, health authorities, insurers or competing distributors must be disclosed by product and route. A material interest requires recusal from the complete case. Compensation cannot depend on supplier selection, delivered volume, inventory, treatment priority or later implementation, and paid commercial introductions are prohibited.

Why the board wants this voice

Risk specialists understand appetite language, operations understands half-life and clinicians understand patient consequence, but none naturally owns the translation across all three. The board lacks an operator who has made bounded allocation and recovery choices under radioactive decay. Independent challenge can expose appetite that sounds prudent yet arrives too late to guide action.

What you will own

• Press management to translate appetite statements into product, route, delay, half-life, patient-consequence and recovery thresholds.
• Test whether dispatch, substitution, allocation, notification and escalation decisions have evidence available before their useful decision clock expires.
• Challenge zero-tolerance language that conceals unavoidable trade-offs or drives every disruption to an unavailable senior executive.
• Probe separation between quality release, radiation safety, clinical judgement, operational allocation and board-level risk acceptance.
• Observe two simulations and identify invented capacity, ambiguous thresholds, late escalation, unsafe substitution and missing patient evidence.
• Shape committee conditions for delegation, override, record retention, periodic threshold testing and retirement of stale assumptions.
• Give the chair a translation diagnostic, case findings, conflict record and questions for the annual risk-appetite review.

Candidate qualifications

• Led isotope, blood, transplant, pharmaceutical or other time-decaying clinical supply under cross-border disruption.
• Has converted board risk appetite into dispatch and allocation thresholds used by operators before options expired.
• Understands quality release, half-life, route reliability, substitution, radiation security and patient consequence together.
• Can distinguish clinical authority, risk acceptance, operational delegation and emergency escalation without blurring accountabilities.
• Challenged absolute service promises where scarcity required transparent priorities and documented trade-offs.
• Maintained independence from producers, couriers, airlines, hospitals and regulators across sensitive clinical-supply decisions.

Non-negotiables

• Can attend five Prague committee sessions, four interface reviews and both continuity simulations.
• Will disclose isotope, radiopharmacy, airline, courier, hospital and health-authority interests before appointment.
• Brings live time-decaying clinical-supply decisions; generic risk-appetite drafting alone is insufficient.
• Accepts no release, safety, dispatch, substitution, allocation, treatment, incident or board-voting authority.

1. 49 words maximum. Describe a clinical-supply decision whose option disappeared because escalation took too long.
2. 49 words maximum. Which producer, courier, airline or hospital relationship could require your recusal?
3. 49 words maximum. How would you translate low missed-delivery appetite when product decay makes zero failure impossible?